The Pharma Data

NOVEMBER 11, 2020

As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”. “As About Selva Therapeutics.

Protein 52

Protein Bioavailability Development Drugs 52

Delveinsight

AUGUST 25, 2020

The drug is directly delivered to lungs via inhalation to achieve high local exposures, and address the concerns of low oral bioavailability linked to niclosamide. . Both the companies have candidates that address the misfolded proteins at the root of disease.

Trials 52

Trials Bioavailability Drugs Protein 52

Roots Analysis

MAY 21, 2024

In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the main causes of drug failure in obtaining approval authorization.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

Delveinsight

FEBRUARY 16, 2021

Padcev is a first-in-class antibody-drug conjugate (ADC) directed against Nectin-4, a protein. The therapy is the first therapy of its kind to target the Nectin-4 protein. Maribavir is an orally bioavailable anti-CMV compound. located on the surface of cells and highly expressed in bladder cancer.

Marketing 52

Marketing Protein Bioavailability Drugs 52

pharmaphorum

NOVEMBER 9, 2022

In ALS , the protein TDP-43 triggers neuroinflammation via activation of the innate immune sensor STING. This novel pathological mechanism is being targeted by NRG and was identified by the company’s collaborator, Professor Seth Masters of Melbourne, Australia’s Walter and Eliza Hall Institute of Medical Research (WEHI).

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

The Pharma Data

NOVEMBER 22, 2020

Alzprotect co-owns or has an exclusive worldwide license from the French National Institute of Health and Medical research (Inserm) and the University of Lille (France) on a total of 58 patents related to Ezeprogind in 39 countries. The company employs 8 people and is supported by BPI France, the National Research Agency and Eurasanté.

Drugs 40

Drugs Protein Bioavailability Development 40

The Pharma Data

DECEMBER 9, 2020

Spun out of CEO and co-founder Evan Feinberg’s breakthrough artificial Intelligence (AI) research at Stanford University’s Pande Lab , Genesis Therapeutics is applying the resulting influential PotentialNet neural network algorithm to unify AI and biotech against a range of diseases with unmet needs. Genesis Therapeutics.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

Delveinsight

JANUARY 7, 2021

Omega Funds led the series B round with assists from fellow new investor Fidelity Management & Research and existing backers Atlas Venture, OrbiMed, and Bristol Myers Squibb, which became involved through its Celgene acquisition. The progress has set Ikena to raise USD 120 million. Hologic acquires Biotheranostics for USD 230 Million.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

Roots Analysis

MARCH 13, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. During our research, we identified over 40 players that offer manufacturing services of biopharmaceutical excipients.

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

Roots Analysis

OCTOBER 2, 2023

Owing to their unique size and physicochemical properties ( surface roughness, surface area, surface energy, crystal structure and shape ), nanoparticles can be widely used as a contrasting agent in medical imaging, a vesicle to cross the blood-brain barrier and a carrier for targeted delivery of genes / drugs, proteins, vaccines and antibiotics.

Drug Delivery 40

Drug Delivery Drugs Bioavailability Development 40

XTalks

SEPTEMBER 19, 2024

We will also explore the next major steps in BTK inhibition research, the challenges in treating B-cell malignancies and the significant breakthroughs achieved during Dr. Mobasher’s tenure at BeiGene. It was engineered to have high potency, bioavailability and kinase selectivity that led to improved efficacy and safety in B-cell malignancies.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

Delveinsight

JULY 30, 2020

Adrenoleukodystrophy (ALD/ X-ALD) is a rare, X-linked disorder secondary to a mutation in the ABCD1 gene, which encodes for a peroxisomal membrane protein, resulting in an excessive accumulation of very-long-chain fatty acids (VLCFAs) in the brain and adrenal glands. A novel, brain penetrant, orally bioavailable and selective PPAR?

Hormones 52

Hormones Marketing Gene Trials 52

XTalks

AUGUST 30, 2022

Clinical research experts from the CRO Medpace shared insights about the operational and regulatory considerations for neuroscience trials with direct CNS administration. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets? Viral Vectors for Gene Delivery to the CNS. The patients are waiting!

Trials 83

Trials Drug Delivery Drugs Gene 83

The Pharma Data

NOVEMBER 19, 2020

Program focused on inhibitors of SARS-CoV-2 main protease, a highly conserved protein essential for viral replication. These compounds have demonstrated high potency in inhibiting the activity of the M pro protease as well as promising oral bioavailability and blood plasma levels in animal studies. References.

Development 40

Development Bioavailability Production Drugs 40

Roots Analysis

JANUARY 28, 2024

Pharmaceutical Research: Big data analytics can be applied in various areas of pharmaceutical research, including drug discovery and development, precision medicine , clinical trial optimization, pharmacovigilance and drug safety, supply chain optimization, and real-time monitoring and surveillance.

Big Data 40

Big Data Medicine Marketing Clinical Trials 40

Delveinsight

SEPTEMBER 8, 2021

Baricitinib, also known as LY3009104 or INCB028050 , is a novel orally bioavailable inhibitor of the tyrosine-protein kinase JAK1 or JAK2. appeared first on DelveInsight Business Research. The drug is also in development for other indications such as Lupus nephritis, Rheumatoid arthritis. Baricitinib (INCB-028050).

Marketing 52

Marketing Sales FDA Approval Antibody 52

XTalks

MARCH 24, 2025

Over time, this leads to proteinuria, where protein leaks into the urine, and eventually to kidney failure. The company is also working on zigakibart, designed to neutralize APRIL, a protein that contributes to kidney inflammation.

Bioavailability 71

Bioavailability Immune Response Protein Bacteria 71